Summary:
A randomized, double-blind, placebo-controlled trial of adjunctive troriluzole in OCD as an adjunct therapy on subjects with OCD who have had inadequate response to their current OCD treatment. The study is approximately 18 weeks long of which the participant will be on study medication for 10 weeks. Visits to the clinic are required approximately every 2 weeks.
Must have a primary diagnosis of OCD of at least 1 year and be experiencing non-response or inadequate response to their current standard of care medication (SSRI). Other criteria will be assessed during pre-screening.
Qualified Participants May Receive:
All study medications, examinations and laboratory testing is provided. A stipend is provided for transportation and time.